Polymorphisms in the MLL breakpoint cluster region (BCR)

Deborah R. Echlin-Bell; Lydia L. Smith; Loretta Li; Pamela L. Strissel; Reiner Strick; Vandana Gupta; Jhula Banerjee; Richard Larson; Mary V. Relling; Susan C. Raimondi; Yasuhide Hayashi; Tomohiko Taki; Nancy Zeleznik-Le; Janet D. Rowley

doi:10.1007/s00439-003-0936-2

Polymorphisms in the MLL breakpoint cluster region (BCR)

Deborah R. Echlin-Bell, Lydia L. Smith, Loretta Li, Pamela L. Strissel, Reiner Strick, Vandana Gupta, Jhula Banerjee, Richard Larson, Mary V. Relling, Susan C. Raimondi, Yasuhide Hayashi, Tomohiko Taki, Nancy Zeleznik-Le, Janet D. Rowley^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

The MLL gene is involved in many chromosomal translocations leading to both acute myeloid and lymphoid leukemia. Some patients treated for primary malignancies with chemotherapeutic agents that inhibit DNA topoisomerase II (topo II) develop treatment-related leukemia (t-AML) caused by MLL gene rearrangement. Whether these patients are unusually susceptible to anti-topo II drugs, or whether this is a random adverse event is unknown. To discover genetic polymorphisms that may predispose patients to t-AML development, we sequenced the 8.3-kb MLL breakpoint cluster region (BCR) from 22 patients who had been treated with topo II inhibitors and who developed t-AML and from 37 patients who did not, and from eight infants and 20 normal individuals. Four polymorphic sites within Alu repetitive elements were identified; three affected the length of poly-A tracts and one altered the size of a trinucleotide repeat. The three poly-A tract polymorphisms occurred with equal frequency in leukemic patients and controls and hence are not predictors of risk. The trinucleotide GAA repeat has three alleles: (GAA)₄, (GAA)₅, and (GAA)₆. The (GAA)₆ allele is very rare. The adult t-AML patients are almost exclusively (GAA)_4/5 heterozygotes (83%), whereas the normal population is only 55% (GAA)_4/5 heterozygotic and is represented equally by (GAA)₄ and (GAA)₅ homozygotes (20% each). Only certain trends could be established because of the small sample size of these leukemic groups. Whereas adult t-AML patients are more likely to be (GAA)_4/5 heterozygotes, this is not statistically significant, and this polymorphism within the MLL BCR has only a suggestive association with t-AML development.

Original language	English (US)
Pages (from-to)	80-91
Number of pages	12
Journal	Human Genetics
Volume	113
Issue number	1
DOIs	https://doi.org/10.1007/s00439-003-0936-2
State	Published - Jul 2003

Funding

Acknowledgements We are grateful to and thank Dr. Cheng Cheng from the Department of Biostatistics at St. Jude Children’s Research Hospital for his statistical help and expertise. We thank Dr. Michelle LeBeau at the University of Chicago for kindly providing the DNA samples from the normal individuals. We thank Paul Gardner at the Howard Hughes Medical Institute of the Uni- versity of Chicago for his assistance in DNA primer preparation and sequencing analysis. D.E.B. was funded by a postdoctoral research fellowship from the Leukemia Research Foundation. D.E.B., L.L.S., R.L., M.V.R., N.Z.L., R.S, P.S., and J.D.R were supported by the PAAR grant (no. U01GM61393-02) from the NIH. R.S., P.S., and J.D.R. were supported by the Harold and Leila Y. Mathers Foundation. J.D.R. also received support from NIH (grant no. CA84405) and The Spastic Paralysis Foundation of the Illinois-Eastern Iowa District of Kiwanis International.

ASJC Scopus subject areas

Genetics
Genetics(clinical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00439-003-0936-2

Cite this

@article{adf539839b284c7282f7ab66ab162c71,

title = "Polymorphisms in the MLL breakpoint cluster region (BCR)",

abstract = "The MLL gene is involved in many chromosomal translocations leading to both acute myeloid and lymphoid leukemia. Some patients treated for primary malignancies with chemotherapeutic agents that inhibit DNA topoisomerase II (topo II) develop treatment-related leukemia (t-AML) caused by MLL gene rearrangement. Whether these patients are unusually susceptible to anti-topo II drugs, or whether this is a random adverse event is unknown. To discover genetic polymorphisms that may predispose patients to t-AML development, we sequenced the 8.3-kb MLL breakpoint cluster region (BCR) from 22 patients who had been treated with topo II inhibitors and who developed t-AML and from 37 patients who did not, and from eight infants and 20 normal individuals. Four polymorphic sites within Alu repetitive elements were identified; three affected the length of poly-A tracts and one altered the size of a trinucleotide repeat. The three poly-A tract polymorphisms occurred with equal frequency in leukemic patients and controls and hence are not predictors of risk. The trinucleotide GAA repeat has three alleles: (GAA)4, (GAA)5, and (GAA)6. The (GAA)6 allele is very rare. The adult t-AML patients are almost exclusively (GAA)4/5 heterozygotes (83%), whereas the normal population is only 55% (GAA)4/5 heterozygotic and is represented equally by (GAA)4 and (GAA)5 homozygotes (20% each). Only certain trends could be established because of the small sample size of these leukemic groups. Whereas adult t-AML patients are more likely to be (GAA)4/5 heterozygotes, this is not statistically significant, and this polymorphism within the MLL BCR has only a suggestive association with t-AML development.",

author = "Echlin-Bell, {Deborah R.} and Smith, {Lydia L.} and Loretta Li and Strissel, {Pamela L.} and Reiner Strick and Vandana Gupta and Jhula Banerjee and Richard Larson and Relling, {Mary V.} and Raimondi, {Susan C.} and Yasuhide Hayashi and Tomohiko Taki and Nancy Zeleznik-Le and Rowley, {Janet D.}",

note = "Funding Information: Acknowledgements We are grateful to and thank Dr. Cheng Cheng from the Department of Biostatistics at St. Jude Children{\textquoteright}s Research Hospital for his statistical help and expertise. We thank Dr. Michelle LeBeau at the University of Chicago for kindly providing the DNA samples from the normal individuals. We thank Paul Gardner at the Howard Hughes Medical Institute of the Uni- versity of Chicago for his assistance in DNA primer preparation and sequencing analysis. D.E.B. was funded by a postdoctoral research fellowship from the Leukemia Research Foundation. D.E.B., L.L.S., R.L., M.V.R., N.Z.L., R.S, P.S., and J.D.R were supported by the PAAR grant (no. U01GM61393-02) from the NIH. R.S., P.S., and J.D.R. were supported by the Harold and Leila Y. Mathers Foundation. J.D.R. also received support from NIH (grant no. CA84405) and The Spastic Paralysis Foundation of the Illinois-Eastern Iowa District of Kiwanis International.",

year = "2003",

month = jul,

doi = "10.1007/s00439-003-0936-2",

language = "English (US)",

volume = "113",

pages = "80--91",

journal = "Human Genetics",

issn = "0340-6717",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Polymorphisms in the MLL breakpoint cluster region (BCR)

AU - Echlin-Bell, Deborah R.

AU - Smith, Lydia L.

AU - Li, Loretta

AU - Strissel, Pamela L.

AU - Strick, Reiner

AU - Gupta, Vandana

AU - Banerjee, Jhula

AU - Larson, Richard

AU - Relling, Mary V.

AU - Raimondi, Susan C.

AU - Hayashi, Yasuhide

AU - Taki, Tomohiko

AU - Zeleznik-Le, Nancy

AU - Rowley, Janet D.

N1 - Funding Information: Acknowledgements We are grateful to and thank Dr. Cheng Cheng from the Department of Biostatistics at St. Jude Children’s Research Hospital for his statistical help and expertise. We thank Dr. Michelle LeBeau at the University of Chicago for kindly providing the DNA samples from the normal individuals. We thank Paul Gardner at the Howard Hughes Medical Institute of the Uni- versity of Chicago for his assistance in DNA primer preparation and sequencing analysis. D.E.B. was funded by a postdoctoral research fellowship from the Leukemia Research Foundation. D.E.B., L.L.S., R.L., M.V.R., N.Z.L., R.S, P.S., and J.D.R were supported by the PAAR grant (no. U01GM61393-02) from the NIH. R.S., P.S., and J.D.R. were supported by the Harold and Leila Y. Mathers Foundation. J.D.R. also received support from NIH (grant no. CA84405) and The Spastic Paralysis Foundation of the Illinois-Eastern Iowa District of Kiwanis International.

PY - 2003/7

Y1 - 2003/7

N2 - The MLL gene is involved in many chromosomal translocations leading to both acute myeloid and lymphoid leukemia. Some patients treated for primary malignancies with chemotherapeutic agents that inhibit DNA topoisomerase II (topo II) develop treatment-related leukemia (t-AML) caused by MLL gene rearrangement. Whether these patients are unusually susceptible to anti-topo II drugs, or whether this is a random adverse event is unknown. To discover genetic polymorphisms that may predispose patients to t-AML development, we sequenced the 8.3-kb MLL breakpoint cluster region (BCR) from 22 patients who had been treated with topo II inhibitors and who developed t-AML and from 37 patients who did not, and from eight infants and 20 normal individuals. Four polymorphic sites within Alu repetitive elements were identified; three affected the length of poly-A tracts and one altered the size of a trinucleotide repeat. The three poly-A tract polymorphisms occurred with equal frequency in leukemic patients and controls and hence are not predictors of risk. The trinucleotide GAA repeat has three alleles: (GAA)4, (GAA)5, and (GAA)6. The (GAA)6 allele is very rare. The adult t-AML patients are almost exclusively (GAA)4/5 heterozygotes (83%), whereas the normal population is only 55% (GAA)4/5 heterozygotic and is represented equally by (GAA)4 and (GAA)5 homozygotes (20% each). Only certain trends could be established because of the small sample size of these leukemic groups. Whereas adult t-AML patients are more likely to be (GAA)4/5 heterozygotes, this is not statistically significant, and this polymorphism within the MLL BCR has only a suggestive association with t-AML development.

AB - The MLL gene is involved in many chromosomal translocations leading to both acute myeloid and lymphoid leukemia. Some patients treated for primary malignancies with chemotherapeutic agents that inhibit DNA topoisomerase II (topo II) develop treatment-related leukemia (t-AML) caused by MLL gene rearrangement. Whether these patients are unusually susceptible to anti-topo II drugs, or whether this is a random adverse event is unknown. To discover genetic polymorphisms that may predispose patients to t-AML development, we sequenced the 8.3-kb MLL breakpoint cluster region (BCR) from 22 patients who had been treated with topo II inhibitors and who developed t-AML and from 37 patients who did not, and from eight infants and 20 normal individuals. Four polymorphic sites within Alu repetitive elements were identified; three affected the length of poly-A tracts and one altered the size of a trinucleotide repeat. The three poly-A tract polymorphisms occurred with equal frequency in leukemic patients and controls and hence are not predictors of risk. The trinucleotide GAA repeat has three alleles: (GAA)4, (GAA)5, and (GAA)6. The (GAA)6 allele is very rare. The adult t-AML patients are almost exclusively (GAA)4/5 heterozygotes (83%), whereas the normal population is only 55% (GAA)4/5 heterozygotic and is represented equally by (GAA)4 and (GAA)5 homozygotes (20% each). Only certain trends could be established because of the small sample size of these leukemic groups. Whereas adult t-AML patients are more likely to be (GAA)4/5 heterozygotes, this is not statistically significant, and this polymorphism within the MLL BCR has only a suggestive association with t-AML development.

UR - http://www.scopus.com/inward/record.url?scp=0037594894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037594894&partnerID=8YFLogxK

U2 - 10.1007/s00439-003-0936-2

DO - 10.1007/s00439-003-0936-2

M3 - Article

C2 - 12665971

AN - SCOPUS:0037594894

SN - 0340-6717

VL - 113

SP - 80

EP - 91

JO - Human Genetics

JF - Human Genetics

IS - 1

ER -

Polymorphisms in the MLL breakpoint cluster region (BCR)

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this